The purpose of this paper was to determine if plasma levels of circulating microRNAs (miRNAs) reported in the literature to be tumor biomarkers are reflective of blood cell counts.
Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies.
Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M
Purpose
Conclusion
46 of the 79 miRNA species previously reported in the literature to be solid tumor biomarkers were highly expressed in at least one blood cell type from a healthy individual. Plasma miRNA expression reflected the blood cell composition of the sample, as plasma levels of miRNA species that exhibited a high level of expression in lymphoid or myeloid cells were correlated with lymphoid and myloid cell counts, respectively, in 43 K2EDTA plasma specimens. Further, levels of miRNA highly expressed in red blood cells were enriched 20-30 fold in plasma when the specimen was hemolyzed. Plasma levels of miRNAs highly expressed in myeloid cells and lymphoid cells shadowed changes in myeloid cell and lymphoid cell counts, respectively, in a patient undergoing myloablative chemotherapy and hematopoetic stem cell transplant.
Studies (1)
Purpose
The purpose of this study was to determine if plasma levels of circulating miRNAs reported in the literature to be tumor biomarkers are reflective of blood cell counts. Blood from a single healthy patient was separated into cellular components and K2EDTA plasma. K2EDTA plasma and complete blood count results were obtained from 42 consecutive patients with a wide range of diagnoses. Further plasma specimens were obtained from a single patient over the course of myloablative chemotherapy. miRNA was isolated on the day of plasma collection and was quantified using individual and array real-time qRT-PCR.
Summary of Findings
46 of the 79 miRNA species previously reported in the literature to be solid tumor biomarkers were highly expressed in at least one blood cell type from a healthy individual. The plasma miRNA expression profile was reflective of the blood cell population, as 42 of the 46 miRNAs that were highly expressed in blood cells were also highly expressed in plasma. Specifically, plasma levels of 4 miRNAs (which were highly expressed in myeloid cells) were correlated with myeloid cell counts in 42 K2EDTA plasma specimens. Plasma levels of an additional miRNA that was highly expressed in lymphoid cells was modestly correlated (r=0.67) with lymphocyte counts, but plasma levels of a liver-specific miRNA were not correlated with any blood cell count. Similarly, levels of 4 miRNA highly expressed in red blood cells were enriched 20-30 fold in plasma when the specimen was hemolyzed, but similar changes in levels of non-red blood cell miRNA were not found after hemolysis. Plasma levels of miRNAs highly expressed in myeloid cells and lymphoid cells mirrored changes in myeloid cell and lymphoid cell counts, respectively, in a patient undergoing myloablative chemotherapy and hematopoetic stem cell transplant.
Biospecimens
FluidBloodFluidPlasmaPreservation Types
None (Fresh)Diagnoses
NormalNeoplasticLymphomaNeoplasticCarcinomaNeoplasticLeukemiaNeoplasticOtherCardiovascular DiseaseOther diagnosesPlatforms
RNALow density arrayRNAReal-time qRT-PCRCell count/volumeFlow cytometryCell count/volumeHematology/ auto analyzerPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Biomarker level A range of complete blood countsBiospecimen Acquisition Time of biospecimen collection 1 day post-infusion1 days pre-infusion11 days post-infusion13 days post-infusion15 days post-infusion27 days post-infusion3 day post-infusion3 days pre-infusion4 days pre-infusion5 days post-infusion5 days pre-infusion7 days post-infusion9 days post-infusionInfusion of hematopoetic stem cellBiospecimen Aliquots and Components Blood and blood products PlasmaWhole bloodBiospecimen Aliquots and Components Hemolysis AbsentPresent